The condition is present in more than half of Medicare patients with stage 3-5 chronic kidney disease.
Low vitamin D status was associated with a 2-fold higher risk for anemia.
Sparsentan could become the first FDA-approved medication for the focal segmental glomerularsclerosis.
In a study, 94.1% of total PTx patients had improvement of bone mineral density at their most affected site.
Surgery decreased the risk of death from any cause by 32% compared with usual treatment.
Just 6.7% of patients had target levels of calcium, phosphorus, and parathyroid hormone a year after surgery.
Sodium zirconium cyclosilicate treatment for 12 months had no clinically meaningful effects on systolic or diastolic pressure, study finds.
Studies also link kidney stone development to osteoporosis and proton pump inhibitor use.
Pending future research, patients should avoid taking more than 120 mg per day.
Their risk of the rare but life-threatening condition is twice as high as in hemodialysis patients.
More patients treated with MWA plus calcitriol reached iPTH levels below 150 pg/mL: 23.33% vs 8.54%.
It also may shorten intensive care unit and hospital length of stay versus late RRT in critically ill patients, meta-analysis reveals.
Educated patients achieved better phosphate binder adherence.
Purgative products introduce 10 times the normal daily amount of phosphorus into the body.
Younger patients are less likely to respond to treatment with sucroferric oxyhydroxide or sevelamer.
The risks of death from any cause were elevated by 22% and 31% for individuals with serum potassium levels of 5.5 mmol/L and 3.2 mmol/L, respectively, compared with 4.2 mmol/L.
PTx patients had 15.7% lower odds of premature death.
Study reveals a link between higher BMI in HD patients and greater incorporation of omega-3 fatty acids into red blood cell membranes.
Study implicates amlodipine, lisinopril, clonidine, acetaminophen, and omeprazole.
Researchers present results from the first long-term study of Urea USP in the United States.
Levels of 10 mg/dL or higher and below 6 mg/dL predicted approximately 50% higher death risk in the 3 months after dialysis initiation.
Cardiovascular events more than tripled 4 days following the last dialysis session.
Prior to starting therapy, parathyroid hormone trajectories show different patterns of increase and decrease.
The percentage of patients with serum phosphorus levels of 5.5 mg/dL and below more than doubled to 37.8% after 6 months of treatment with sucroferric oxyhydroxide.
Patients also needed fewer phosphate binder pills over time.
Death risk increased markedly once serum potassium values exceeded 5.5 mEq/L.
Having 3 or 4 CKD-MBD markers in the danger zone more than doubled the chances of early death.
From 2001 to 2014, the prevalence of microalbuminuria among obese individuals without other comorbidities increased from 3.2% to 8.1%.
Calcitriol and paricalcitol raise levels of fibroblast growth factor 23 and sclerostin and lower levels of some bone turnover markers.
Evidence suggests decreased sodium absorption could be a contributing factor in at least some patients.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)